European Innovation Council

Chipiron is a developer of advanced portable MRI machines that utilize cutting-edge quantum detectors to generate high-resolution three-dimensional anatomical images. By operating at ultra-low magnetic fields, these machines are designed to be lightweight and cost-effective, significantly reducing the price compared to traditional MRI systems. Chipiron's technology aims to enhance disease detection, diagnosis, and treatment monitoring, particularly for brain-related conditions, thereby assisting healthcare institutions in improving patient outcomes and potentially decreasing fatality rates associated with these ailments.

QDI Systems B.V. is a startup based in Groningen, the Netherlands, focused on developing advanced imaging devices for medical applications using quantum dot technology. The company specializes in creating X-ray sensors that deliver high-contrast and high-resolution imaging, particularly for mammography, while also reducing radiation exposure for patients. QDI Systems aims to provide user-friendly quantum dot materials accompanied by comprehensive instructions for constructing high-performance imaging devices. By leveraging innovative technology, the company enhances the precision of medical imaging, enabling healthcare professionals to obtain critical diagnostic information efficiently and safely.

QDI Systems B.V. is a startup based in Groningen, the Netherlands, focused on developing advanced imaging devices for medical applications using quantum dot technology. The company specializes in creating X-ray sensors that deliver high-contrast and high-resolution imaging, particularly for mammography, while also reducing radiation exposure for patients. QDI Systems aims to provide user-friendly quantum dot materials accompanied by comprehensive instructions for constructing high-performance imaging devices. By leveraging innovative technology, the company enhances the precision of medical imaging, enabling healthcare professionals to obtain critical diagnostic information efficiently and safely.

Acorai is a medical device company focused on developing a non-invasive heart failure monitoring platform that centers around direct intracardiac pressure monitoring (ICPM). The company utilizes a unique combination of sensor technologies and machine learning to enable accurate and cost-effective heart failure management. Acorai's technology allows for the non-invasive monitoring of cardiac and pulmonary pressure through the analysis of acoustic, vibratory, and waveform data, making it the only proven method to enhance outcomes for heart failure patients. The device has received clinical validation and has been designated as an FDA Breakthrough Device, with plans to enter the market in 2025. By enabling healthcare professionals to proactively adjust medications, Acorai aims to reduce both the rates of heart failure re-hospitalization and mortality.

Sequentia Biotech, founded in 2013 by Walter Sanseverino and Riccardo Aiese Cigliano, is a bioinformatics company based at the UAB Research Park. The company specializes in transforming genomic data into actionable knowledge for various sectors including academic research, plant and animal breeding, and biomedicine. Sequentia serves a diverse client base of over 30 public and private research centers, companies, and hospitals, participating in more than 160 R&D projects. The company offers cloud software, custom software, and bioinformatics consulting services, with notable contributions such as two open-source biodata banks and an award-winning R&D line called Tricopharming, established in 2014. Sanseverino and Aiese have published over 40 scientific articles in high-impact journals, underscoring the company's expertise in omics sciences.

Oryl Photonics specializes in developing laboratory instruments for pharmaceutical and biotech companies. Their core product provides a simple, reliable, and cost-effective method for measuring solubility, contributing to accelerated drug development and improved medicine. The company's unique technology preserves valuable substances during testing, offering a solubility measurement service that empowers researchers to make data-driven decisions and expedite product development.

Endoron Medical is a company focused on developing innovative medical devices aimed at enhancing the treatment of abdominal aortic aneurysms. The company specializes in creating an endovascular suture and a fixation device for endografts, which are essential for patients undergoing endovascular aneurysm repair. By employing advanced technology, Endoron Medical aims to provide long-lasting sealing solutions that improve patient outcomes and support healthcare professionals in effectively managing this serious condition.

UroMems is a medical device company dedicated to addressing specific clinical needs related to urinary conditions that significantly impact patients' quality of life. The company specializes in the design, development, and commercialization of active implantable medical devices. Its innovative approach aims to enhance existing surgical treatments by minimizing associated side effects and ensuring that patients receive appropriate care promptly. Through its commitment to improving treatment options, UroMems seeks to benefit a wide range of patients facing urinary health challenges.

BOYDSense is a medical device company founded in 2015 and headquartered in South San Francisco, California. The company specializes in developing non-invasive and affordable tools for measuring critical biomarkers through exhaled breath. BOYDSense focuses on breath-based metabolomics, which involves capturing, identifying, and quantifying volatile organic compound (VOC) biomarker patterns found in human breath. This innovative approach enables medical professionals to simplify the monitoring, screening, and risk stratification of chronic diseases, facilitating more effective diagnosis and ongoing management of these conditions.

RespiQ is a healthtech startup focused on developing portable, non-invasive breath analysis technology for the early detection and management of respiratory diseases. The company employs advanced emission spectroscopy and artificial intelligence to identify volatile organic compounds in breath, facilitating real-time detection of conditions such as COPD exacerbations. RespiQ emphasizes affordability, portability, and user-friendliness to democratize access to advanced diagnostics, thereby enhancing patient outcomes and reducing healthcare costs. In addition to its primary focus on respiratory diseases, RespiQ's versatile platform technology has potential applications for conditions such as asthma, lung cancer, and infectious diseases. The company also offers an intuitive app that provides personalized health insights, allowing users to monitor changes in their health and make informed dietary choices, ultimately empowering individuals to improve their overall well-being.

Acorai is a medical device company focused on developing a non-invasive heart failure monitoring platform that centers around direct intracardiac pressure monitoring (ICPM). The company utilizes a unique combination of sensor technologies and machine learning to enable accurate and cost-effective heart failure management. Acorai's technology allows for the non-invasive monitoring of cardiac and pulmonary pressure through the analysis of acoustic, vibratory, and waveform data, making it the only proven method to enhance outcomes for heart failure patients. The device has received clinical validation and has been designated as an FDA Breakthrough Device, with plans to enter the market in 2025. By enabling healthcare professionals to proactively adjust medications, Acorai aims to reduce both the rates of heart failure re-hospitalization and mortality.

Epigene Labs SAS is a biotechnology firm focused on enhancing precision oncology through its advanced technology platform that utilizes artificial intelligence. Founded in 2019 and headquartered in Paris, France, with an additional office in Boston, Massachusetts, the company addresses the significant challenges of aggregating, analyzing, and visualizing extensive genomic data in cancer research. By integrating proprietary data from partners with publicly available datasets, Epigene Labs provides medical researchers with actionable insights and user-friendly analytics. The company collaborates with leading cancer centers and prominent biotech firms to develop intelligence-augmenting services that support drug discovery and research in precision oncology. Its innovative approach aims to transform genomic data into effective strategies for targeted cancer therapies.

EyeControl is a medical technology company that develops innovative communication solutions for individuals with severe speech impairments, such as those affected by locked-in syndrome or ALS. Their flagship product is an intuitive glass frame equipped with an infrared camera, which translates eye movements into spoken commands via a connected computer and earphones/speaker. This device aims to enhance patients' quality of life by facilitating easier communication and improving access to healthcare services.

Innitius specializes in developing diagnostic devices aimed at enhancing women's health, particularly in the context of preterm birth. Utilizing innovative torsional ultrasound technology, the company has created a patented intravaginal probe that transmits torsional waves to assess changes in tissue consistency. This technology enables medical practitioners to evaluate the risk of preterm birth and the likelihood of successful labor induction. By providing actionable diagnostics, Innitius helps healthcare providers accurately identify false indications of premature labor, thereby improving patient care and outcomes in obstetrics.

ADmit Therapeutics, S.L. is a biotechnology company based in Begues, Spain, focused on developing diagnostic tests for the early detection of Alzheimer’s disease. Founded in 2017, the company utilizes epigenetic analysis of blood samples to identify a series of mitochondrial biomarkers, which are unrelated to traditional markers such as ß-amyloid or tau. By employing next-generation sequencing to analyze methylcytosines in mitochondrial DNA, ADmit Therapeutics provides medical practitioners with a simplified method for detecting early-stage Alzheimer’s disease. This innovative approach not only aids in diagnosis but also supports pharmaceutical companies in the accelerated identification of potential curative drugs.

Neuro Event Labs Oy, established in 2015 and headquartered in Tampere, Finland, specializes in developing artificial intelligence-based software for epilepsy patient monitoring. Their primary product collects accurate seizure data from patients at home and in hospitals, which is then analyzed and relayed to physicians for informed treatment decisions. This solution was developed in close collaboration with leading Finnish hospitals.

EBAMed SA is a Swiss startup based in Geneva that specializes in developing innovative medical devices for the non-invasive treatment of heart arrhythmias. Founded in 2018, the company focuses on creating an ultrasound-based device that utilizes proton therapy to monitor heart motion and synchronize therapeutic beams in real time. This technology allows for the precise delivery of radiation treatment to targeted heart tissues, thereby expanding treatment options for existing proton therapy centers and enabling them to treat heart patients effectively. By providing a non-invasive approach to cardiac care, EBAMed aims to improve patient outcomes and streamline treatment processes in outpatient settings.

Tada Group AB, founded in 2016 and headquartered in Stockholm, Sweden, specializes in the manufacturing of medical products, primarily focusing on intravenous solutions. The company offers products such as the Thoor infusion tube, which is designed for efficiency in medical applications. Additionally, Tada Group has developed the ReLink connector, an innovative solution aimed at minimizing complications and costs related to accidental disconnections in IV lines, which is a significant issue in both hospital and homecare environments. Through its product offerings, Tada Group addresses critical challenges in healthcare, enhancing safety and reliability in infusion practices.

Molecular Attraction is a research and development firm focused on creating innovative solutions for vector-borne disease control and eradication. The company specializes in identifying biological compounds that can influence the behavior of various vector organisms, including mosquitoes, ticks, flies, and rodents. By utilizing sustainable technology and chemical blends, Molecular Attraction aims to provide effective, long-lasting, and low-maintenance pest control solutions. Their approach is designed to enhance the efficacy of vector-borne disease management while prioritizing environmental sustainability and cost-effectiveness within the pest control industry.

iLoF, or Intelligent Lab on Fiber, is a technology company specializing in the integration of photonics and artificial intelligence to enhance drug discovery and development. The company has developed a patented system that identifies and captures unique features of gold-standard biomarkers, creating a cloud-based digital library of these biological profiles. This platform allows for the collection of extensive data, which facilitates personalized medicine by enabling healthcare companies to conduct more efficient and patient-centric clinical trials. By employing a multidisciplinary approach that involves physicists, biologists, and data scientists, iLoF aims to accelerate the development of tailored treatments, ultimately improving patient outcomes and reducing the costs associated with drug development.

Arctic Therapeutics is a drug discovery and development company that focuses on identifying the genetic underpinnings of both rare and common diseases. Utilizing bioinformatic approaches and artificial intelligence, the company aims to mitigate the risks associated with traditional drug development while significantly reducing the costs and time required to bring effective treatments to patients. With over 20 years of expertise in international genomics research, Arctic Therapeutics employs an innovative methodology in its drug development efforts. Collaborating closely with the Center for Applied Genomics at the Children's Hospital of Philadelphia, the company is actively involved in repurposing and developing breakthrough medical treatments. Notably, Arctic Therapeutics is working on a drug candidate for Alzheimer’s disease that has the potential to become the first cure for dementia, addressing both treatment and prevention. The company was inspired by Dr. Hakon Hakonarson, a prominent figure in applied genomics, whose work has been recognized as pioneering in the field of genetic research and therapeutic development.

Arctic Therapeutics is a drug discovery and development company that focuses on identifying the genetic underpinnings of both rare and common diseases. Utilizing bioinformatic approaches and artificial intelligence, the company aims to mitigate the risks associated with traditional drug development while significantly reducing the costs and time required to bring effective treatments to patients. With over 20 years of expertise in international genomics research, Arctic Therapeutics employs an innovative methodology in its drug development efforts. Collaborating closely with the Center for Applied Genomics at the Children's Hospital of Philadelphia, the company is actively involved in repurposing and developing breakthrough medical treatments. Notably, Arctic Therapeutics is working on a drug candidate for Alzheimer’s disease that has the potential to become the first cure for dementia, addressing both treatment and prevention. The company was inspired by Dr. Hakon Hakonarson, a prominent figure in applied genomics, whose work has been recognized as pioneering in the field of genetic research and therapeutic development.

Sonio is an AI-based support platform for fetal ultrasound, helping practitioners analyze and diagnose congenital malformations. Sonio combines the patient’s medical history, genetic and biological data, and ultrasound semiology to assist physicians on the path to the right diagnosis. It assists sonographers during prenatal screening scans, helping them ensure that they have not forgotten anything, take risk factors into account, and facilitate the sharing of images with patients and other health professionals.

Sonio is an AI-based support platform for fetal ultrasound, helping practitioners analyze and diagnose congenital malformations. Sonio combines the patient’s medical history, genetic and biological data, and ultrasound semiology to assist physicians on the path to the right diagnosis. It assists sonographers during prenatal screening scans, helping them ensure that they have not forgotten anything, take risk factors into account, and facilitate the sharing of images with patients and other health professionals.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, established in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm specializes in developing advanced diagnostics for the early detection of various cancers, focusing on Stage I and Stage II malignancies where timely intervention can significantly improve patient outcomes. Utilizing a combination of infrared spectroscopy and artificial intelligence, Dxcover's technology enables the detection of cancer from a simple blood sample, allowing for same-day diagnosis and patient stratification. This innovative approach aims to enhance treatment options and ultimately improve survival rates and quality of life for patients.

Nano4Imaging GmbH, established in 2011 and located in Aachen, Germany, specializes in the development and production of contrast agents and devices designed for in-vivo imaging of medical implants and minimally invasive devices. The company offers a range of products, including MRWire EmeryGlide, a magnetic resonance imaging (MRI) conditional guidewire, and various coatings under the MagnaFy brand that enhance the visibility of devices in different imaging modalities, such as MRI, computed tomography (CT), and X-ray. These innovations facilitate navigation and monitoring during medical interventions, particularly in the treatment of cardiovascular diseases and in radiotherapy. By leveraging advanced nanotechnology, Nano4Imaging aims to improve the accuracy of patient monitoring and intervention outcomes.

Sightic Analytics specializes in developing AI-powered software that enables real-time analysis of drug effects through image analysis of the eye area. Utilizing a mobile phone's camera, the company's technology captures a short film sequence of an individual's eye, focusing on pupil responses to detect the presence of drugs. This innovative approach allows for efficient and discreet drug testing, making it suitable for use in various settings, including workplace environments. Sightic's solution aims to streamline the drug screening process while minimizing privacy concerns, enabling employers to monitor employee health effectively.

CorWave is a company focused on developing innovative implanted cardiac support devices aimed at improving the quality of life for patients suffering from heart failure. Its flagship product, the CorWave LVAD, employs a unique undulating disc wave pumping mechanism, which replaces traditional high-speed impellers used in current continuous flow rotary pumps. This design significantly reduces trauma to blood, thereby minimizing complications such as clotting and bleeding. The CorWave pump generates a pulsatile flow that closely resembles the natural heartbeat, addressing a key limitation of existing LVADs that provide only continuous flow. Additionally, the device's low power consumption and compact size facilitate its potential for complete implantation, enhanced by a wireless energy transfer system. Through these advancements, CorWave aims to alleviate the burdens associated with heart failure and invasive surgical procedures.

Carmat is a French medtech company that specializes in the development and manufacturing of bioprosthetic artificial hearts. Founded in 2008 and headquartered in Vélizy-Villacoublay, the company creates biocompatible, auto-regulated total artificial hearts designed to closely mimic the human heart's structure, including both right and left ventricles. These devices are intended for patients suffering from chronic terminal heart failure classified as class IV by the New York Heart Association, as well as those experiencing acute terminal heart failure due to massive myocardial infarction. Carmat aims to provide a reliable and innovative therapeutic solution for heart failure patients who are ineligible for transplants and have exhausted other treatment options. In addition to the artificial hearts, the company develops the necessary power supply systems and remote diagnostic systems for these devices.

Afon Technology specializes in the development of non-invasive blood glucose monitoring devices aimed at benefiting individuals with diabetes. The company’s innovative technology allows for real-time, pain-free tracking of blood glucose levels, offering features such as continuous detection, potential pre-diabetic identification, and alarm alerts for high and low glucose levels. Users can access trend profiles and time-in-range statistics through a user-friendly app compatible with both iOS and Android systems. Additionally, Afon Technology’s device can transform any smartwatch into a glucose monitoring tool, providing fast and accurate measurements, data logging, and personalized health trends. This approach enhances daily management for diabetics, ultimately reducing the risk of diabetes-related complications.

ALA Diagnostics specializes in the development and marketing of in vitro diagnostic kits aimed at addressing prevalent pathologies and unresolved medical needs. The company focuses on creating diagnostic solutions, including kits specifically designed for the early diagnosis of multiple sclerosis. These kits are engineered for seamless integration into the clinical routines of hospitals and medical centers, allowing healthcare professionals to deliver accurate results efficiently. By improving diagnostic capabilities, ALA Diagnostics contributes to enhancing the quality of life for individuals affected by multiple sclerosis and potentially other conditions, leveraging synergies with public organizations renowned for their innovative project initiatives.

Avatar Medical is a developer of a virtual reality medical platform that creates 3D patient avatars to assist surgeons in visualizing medical images. By generating interactive representations based on medical data, the platform enables clinicians to accurately and instantly access critical clinical information. This innovative approach not only enhances the understanding of surgical options but also facilitates the training of medical fellows and improves patient engagement. Avatar Medical aims to transform how medical professionals interact with imaging data, ultimately contributing to better surgical outcomes and patient care.

ValueBiotech Srl is a medical device company focused on developing robotic surgical tools that enhance laparoscopic techniques. Designed by practicing surgeons, these innovative tools integrate seamlessly into operating rooms, enabling surgeons to perform procedures through a single incision or natural orifices, resulting in a painless and scarless experience for patients. The company's mission is to improve clinical outcomes while ensuring safety and cost-effectiveness in surgical practices. By transforming traditional surgical methods, ValueBiotech aims to provide better healthcare solutions for millions of patients each year.

Carmat is a French medtech company that specializes in the development and manufacturing of bioprosthetic artificial hearts. Founded in 2008 and headquartered in Vélizy-Villacoublay, the company creates biocompatible, auto-regulated total artificial hearts designed to closely mimic the human heart's structure, including both right and left ventricles. These devices are intended for patients suffering from chronic terminal heart failure classified as class IV by the New York Heart Association, as well as those experiencing acute terminal heart failure due to massive myocardial infarction. Carmat aims to provide a reliable and innovative therapeutic solution for heart failure patients who are ineligible for transplants and have exhausted other treatment options. In addition to the artificial hearts, the company develops the necessary power supply systems and remote diagnostic systems for these devices.

Brainhero is a life science company that specializes in home-based neurofeedback therapy aimed at assisting individuals with neurological impairments, particularly children diagnosed with Autism Spectrum Disorder (ASD) and Attention Deficit Hyperactivity Disorder (ADHD). The company utilizes an innovative approach that enables users to train their brain activity through an engaging and playful interface. By measuring brain waves with an electroencephalogram (EEG) and visualizing the data in a mobile application, children can learn to enhance their concentration and relaxation skills. Brainhero's services also support medical practitioners in early prediction of neurological issues and in adjusting medication dosages for patients experiencing various conditions, including intellectual disabilities, epilepsy, and anxiety.

Novus Diagnostics is focused on developing an innovative diagnostic device aimed at detecting sepsis. This technology allows for the rapid and automated identification of pathogens present in whole blood samples. By providing results in minutes, Novus Diagnostics empowers healthcare providers to initiate effective treatment for sepsis patients quickly and efficiently. The approach not only enhances patient care but also aims to reduce costs associated with sepsis management.

Positrigo AG is a Zurich-based company specializing in the development, manufacturing, and sales of dedicated brain positron emission tomography (PET) scanners. Founded in 2018, Positrigo focuses on providing functional imaging solutions that facilitate the early detection of neurodegenerative diseases, particularly Alzheimer's disease, as well as other conditions like Lewy body dementia, vascular dementia, and frontotemporal dementia. The company's PET scanners are designed to be accessible and affordable, enabling healthcare professionals to diagnose and monitor treatment effectively, while also contributing to the advancement of new therapies in the field of neurology.

VesselSens, headquartered in Bonn, Germany, specializes in medical technology. It develops and markets implantable sensor systems designed to detect restenosis, a common complication following stent implantation or balloon angioplasty. These wireless sensors, placed in coronary or peripheral arteries, monitor vascular constrictions in real-time, aiding doctors in timely diagnosis and treatment.

Nanordica Medical is an Estonian medical technology company specializing in advanced wound care solutions. The company has developed a patented nanotechnology that combines copper and silver in nanofibers to effectively remove infections and promote healing in chronic wounds. Nanordica Medical has launched a veterinary product, Ravimus Vet, designed for treating animal wounds, while also focusing on a first-in-class wound dressing for challenging human conditions, such as diabetic foot ulcers. Recent clinical trials have demonstrated that their wound dressing outperforms traditional silver ion-based dressings across multiple efficacy parameters, offering a more powerful antibacterial effect that can inactivate a wider range of bacteria, including drug-resistant strains.

Sightic Analytics specializes in developing AI-powered software that enables real-time analysis of drug effects through image analysis of the eye area. Utilizing a mobile phone's camera, the company's technology captures a short film sequence of an individual's eye, focusing on pupil responses to detect the presence of drugs. This innovative approach allows for efficient and discreet drug testing, making it suitable for use in various settings, including workplace environments. Sightic's solution aims to streamline the drug screening process while minimizing privacy concerns, enabling employers to monitor employee health effectively.

Innitius specializes in developing diagnostic devices aimed at enhancing women's health, particularly in the context of preterm birth. Utilizing innovative torsional ultrasound technology, the company has created a patented intravaginal probe that transmits torsional waves to assess changes in tissue consistency. This technology enables medical practitioners to evaluate the risk of preterm birth and the likelihood of successful labor induction. By providing actionable diagnostics, Innitius helps healthcare providers accurately identify false indications of premature labor, thereby improving patient care and outcomes in obstetrics.

Kahun is a healthcare technology company that offers an online medical platform designed to assist physicians in making informed clinical decisions. By cataloging clinical information from peer-reviewed medical literature, Kahun's platform employs artificial intelligence diagnostic engines to extract relevant insights. This approach not only streamlines the clinical intake process but also enhances the transparency and explainability of healthcare decisions. By optimizing physicians' documentation time and overall cognitive load, Kahun aims to improve clinical outcomes and facilitate faster, evidence-based decision-making within healthcare organizations.

Restore Medical is a medical device company based in Or Yehuda, Israel, established in 2016. The company specializes in providing innovative treatment solutions for patients suffering from congestive heart failure. Its flagship product, ContraBand, is a catheter-delivered implant designed specifically for patients with left ventricle failure who have preserved right ventricle function. This device aims to enhance left ventricle ejection fraction, minimize mitral regurgitation, and restore optimal ventricular geometry. By addressing these critical issues, Restore Medical's technology seeks to significantly improve patient quality of life and decrease rates of hospital readmission.

Idoven is a pioneering company that has created the world’s first cardiology-as-a-service platform utilizing artificial intelligence to enhance the capabilities of both cardiologists and non-cardiology clinicians in identifying, triaging, and diagnosing patients on a large scale. The company's innovative software analyzes prolonged electrocardiograms to detect early signs of heart problems, including alterations in cardiac electrical activity and arrhythmias, thereby facilitating timely diagnoses and preventing serious conditions such as myocardial infarction and sudden cardiac death. Idoven has established partnerships with prominent organizations, including AstraZeneca, Abbott, and GE Healthcare, and has gained recognition in the healthcare sector, receiving multiple awards for its AI technology from notable institutions in Europe and the United States. The company has also been recognized as one of the top 50 companies in Digital Health for 2023 by CB Insights.

PoroUS combines non-ionizing 3D ultrasound technology and image guidance with sophisticated spectral signal processing to ensure the osteoporosis diagnosis. PoroUS’ cortical ultrasound back-scatter analysis offers a novel way to detect microstructural changes (porosity and thickness) in the cortical bone. PoroUS provides a precision- and operating independence-tool, which will improve the cost effectiveness and reduce the economic burden by preventing fragility fractures.

Oivi is a Norwegian company founded in 2017 and based in Oslo, specializing in the development of an affordable AI-driven camera and platform for the identification of diabetic eye diseases. The company focuses on facilitating retinal screening in primary care settings, thereby promoting awareness and proactive management of diabetic eye health. Oivi's innovative platform employs automated image capture and diagnostic capabilities to monitor eye diseases effectively through teleconsultation. With a multifaceted team possessing extensive expertise in camera and software development, Oivi aims to empower patients to prevent permanent vision loss associated with diabetes.

Endoron Medical is a company focused on developing innovative medical devices aimed at enhancing the treatment of abdominal aortic aneurysms. The company specializes in creating an endovascular suture and a fixation device for endografts, which are essential for patients undergoing endovascular aneurysm repair. By employing advanced technology, Endoron Medical aims to provide long-lasting sealing solutions that improve patient outcomes and support healthcare professionals in effectively managing this serious condition.

PoroUS combines non-ionizing 3D ultrasound technology and image guidance with sophisticated spectral signal processing to ensure the osteoporosis diagnosis. PoroUS’ cortical ultrasound back-scatter analysis offers a novel way to detect microstructural changes (porosity and thickness) in the cortical bone. PoroUS provides a precision- and operating independence-tool, which will improve the cost effectiveness and reduce the economic burden by preventing fragility fractures.

Hy2Care BV is a start-up emerging from the University of Twente in the Netherlands, focused on developing innovative treatments for osteoarthritis, a condition that affects over 100 million individuals in the Western world. The company's primary product is an injectable hydrogel designed to repair cartilage defects, specifically in the knee. This bioresorbable hydrogel consists of a two-component system made from a mixture of natural polymer conjugates that undergo a mild enzymatic reaction to form a cross-linked structure. Hy2Care aims to provide an effective treatment option for osteoarthritis, addressing a significant unmet medical need and enhancing the quality of life for patients suffering from this debilitating condition.

Hy2Care BV is a start-up emerging from the University of Twente in the Netherlands, focused on developing innovative treatments for osteoarthritis, a condition that affects over 100 million individuals in the Western world. The company's primary product is an injectable hydrogel designed to repair cartilage defects, specifically in the knee. This bioresorbable hydrogel consists of a two-component system made from a mixture of natural polymer conjugates that undergo a mild enzymatic reaction to form a cross-linked structure. Hy2Care aims to provide an effective treatment option for osteoarthritis, addressing a significant unmet medical need and enhancing the quality of life for patients suffering from this debilitating condition.

Neurosoft Bioelectronics is a Swiss company specializing in the development of soft implantable electrodes designed for interfacing with the nervous system. The company focuses on creating advanced neural implants that can record and stimulate the brain, spinal cord, and peripheral nerves, addressing the limitations of traditional stiff devices that hinder patient outcomes. Its flagship product, the SOFT ECoG, is a subdural electrode that facilitates effective brain monitoring and stimulation while minimizing electrical resistance and MRI artifacts. This innovative technology aims to achieve long-term bio-integration with neural tissues, adapting to both static and dynamic mechanical properties, which enhances therapeutic capabilities for patients suffering from neurological disorders. Ultimately, Neurosoft Bioelectronics strives to improve clinical outcomes and expand the potential applications of neural interfaces in healthcare.

Genetika+ is a medical platform focused on personalizing treatment for depression by utilizing advanced biological, medical, and genetic data. The company has developed an innovative testing tool that predicts the most effective drug therapy for individual patients, thus enabling faster treatment solutions with reduced side effects and lower dosing requirements. By employing a combination of stem-cell technology, genomics, and artificial intelligence, Genetika+ aims to optimize treatment while also aiding pharmaceutical companies in enhancing their product offerings and streamlining clinical trials. This approach not only tailors treatments to specific patient needs but also seeks to advance care for psychiatric and neurological conditions.

InVera Medical is focused on developing innovative medical devices aimed at treating varicose veins and venous ulcers. The company is creating BioVena™, a less invasive and pain-free treatment option that utilizes the body's natural biological response to address venous diseases. This proprietary technology positions InVera Medical to significantly improve patient outcomes by providing a safer and more effective alternative to existing treatment methods. With only a small fraction of the 120 million individuals suffering from venous disease receiving adequate endovenous treatment annually, InVera Medical seeks to broaden access to effective care for a population largely underserved by current solutions. The company’s advancements are particularly crucial given the high annual costs associated with venous ulcers, which amount to approximately $33 billion for insurers in the US and EU. By targeting the full spectrum of venous disease, InVera Medical aims to enhance the quality of life for patients who have long been limited to ineffective compression bandaging.

Peili Vision Oy is a company based in Helsinki, Finland, specializing in virtual reality technology for neurological rehabilitation. Established in 2015, the company has developed a software platform that empowers therapists to design tailored training environments for various therapeutic disciplines, including speech and language pathology, neuropsychology, and occupational therapy. Peili Vision's innovative approach integrates gamification, data analytics, and remote rehabilitation services, allowing healthcare professionals to engage patients in immersive exercises that adapt to their individual needs. This technology facilitates customizable learning experiences, enabling therapists to monitor progress and provide feedback effectively. Peili Vision serves both private and public healthcare clients and operates an additional office in Oulu, Finland.

Thericon is a medical technology company specializing in multiparametric imaging solutions for surgical procedures. It offers a proprietary system that helps surgeons distinguish various tissue types and identify malignant lesions, enhancing surgical accuracy and aiding in informed treatment decisions.

Dermagnostix is a German company founded in 2020, located in the Freiburg and Munich areas. It specializes in developing innovative dermatology diagnostics aimed at enhancing clinical practice and improving patient experiences. The company offers a molecular diagnostic platform that facilitates rapid and objective diagnostics for skin diseases, particularly in distinguishing between eczema and psoriasis at a molecular level. This technology empowers healthcare professionals to provide better care and treatment options, ultimately improving the lives of patients with dermatological conditions.

Betalin Therapeutics is a privately-held company dedicated to developing innovative cell therapy solutions for insulin-dependent diabetes through its Engineered Micro-Pancreas (EMP) technology. This platform combines harvested pancreatic islets, known as Islets of Langerhans, with a proprietary biological micro-environment designed to support these cells. The EMP aims to offer an alternative to traditional insulin therapy, potentially eliminating the need for insulin injections and glucose monitoring in patients. Following promising in-vitro and preliminary in-vivo results, Betalin Therapeutics is focused on optimizing the therapy using animal models and preparing to submit an Investigational New Drug (IND) application to the FDA in anticipation of advancing to clinical trials.

Aligned Bio is a developer of advanced nanowire-based biosensor platforms that cater to various industries, including biomedicine, water purification, public safety, and personal electronics. The company specializes in creating sensors that are fast, accurate, and highly sensitive, which are essential for a range of applications such as disease diagnosis, pathogen and pesticide identification, and pollution monitoring. Aligned Bio enhances the sensitivity of its biosensors through patented methods for nanowire production and alignment. By providing sensor manufacturers with large-area nanowires and improved signal capacity at a low cost, Aligned Bio aims to advance sensor-based technologies across multiple sectors.

BOYDSense is a medical device company founded in 2015 and headquartered in South San Francisco, California. The company specializes in developing non-invasive and affordable tools for measuring critical biomarkers through exhaled breath. BOYDSense focuses on breath-based metabolomics, which involves capturing, identifying, and quantifying volatile organic compound (VOC) biomarker patterns found in human breath. This innovative approach enables medical professionals to simplify the monitoring, screening, and risk stratification of chronic diseases, facilitating more effective diagnosis and ongoing management of these conditions.

Filterlex Medical Ltd., established in 2015 and based in Yokneam, Israel, specializes in developing innovative embolic protection devices for the cardiovascular field. The company's flagship product, CAPTIS, is a full-body embolic protection device designed to reduce the risk of stroke and other complications during catheter-based structural heart procedures. Filterlex aims to address the limitations of current products by offering a device that can be intuitively deployed and retrieved, providing comprehensive protection by deflecting, capturing, and removing embolic particles. The company is currently seeking seed funding to support its growth and product development efforts.

Xsensio is a digital health company focused on addressing the critical challenge of real-time and continuous monitoring of health parameters. The company has developed an innovative Lab-on-Skin wearable device, which serves as a modular miniaturized sensing platform. This device enables the continuous and real-time analysis of biochemical information, including proteins and hormones, at the surface of the skin. By providing unprecedented access to a wide range of biochemical parameters found in sweat, such as electrolytes and metabolites, Xsensio aims to enhance patient care in a simple and minimally invasive manner. Through this technology, the company seeks to transform healthcare from a static approach to a more dynamic and responsive model.

Criam is a biotechnology company based in Braga, Portugal, founded in 2015. It specializes in the research and development of a medical device that facilitates blood type analysis and the detection of various infectious diseases, including HIV, Brucella, tick fever, syphilis, mononucleosis, and meningitis. The company's portable platform operates independently of electricity and does not require additional laboratory infrastructure, making it accessible for use in diverse settings. Criam's device allows for rapid and accurate blood testing, which enhances clinical decision-making by providing timely health information. The technology is designed to be scalable, with one reader capable of performing multiple tests using specialized cartridges and computer vision algorithms. This innovation aims to improve the efficiency and reliability of blood testing services, ultimately enhancing patient care.

Tada Group AB, founded in 2016 and headquartered in Stockholm, Sweden, specializes in the manufacturing of medical products, primarily focusing on intravenous solutions. The company offers products such as the Thoor infusion tube, which is designed for efficiency in medical applications. Additionally, Tada Group has developed the ReLink connector, an innovative solution aimed at minimizing complications and costs related to accidental disconnections in IV lines, which is a significant issue in both hospital and homecare environments. Through its product offerings, Tada Group addresses critical challenges in healthcare, enhancing safety and reliability in infusion practices.

Aligned Bio is a developer of advanced nanowire-based biosensor platforms that cater to various industries, including biomedicine, water purification, public safety, and personal electronics. The company specializes in creating sensors that are fast, accurate, and highly sensitive, which are essential for a range of applications such as disease diagnosis, pathogen and pesticide identification, and pollution monitoring. Aligned Bio enhances the sensitivity of its biosensors through patented methods for nanowire production and alignment. By providing sensor manufacturers with large-area nanowires and improved signal capacity at a low cost, Aligned Bio aims to advance sensor-based technologies across multiple sectors.

Intelligent Implants is a bioelectronics company based in Cork, Ireland, founded in 2014 by Erik Zellmer, Rory Murphy, Martin Larsson, and John Zellmer. The company specializes in wireless implantable electronics designed to stimulate, steer, and monitor bone growth. Its innovative electrotherapeutic devices provide solutions to treat diseases and facilitate the recovery of bone and other tissues. By integrating data, engineering, and medical expertise, Intelligent Implants develops active and connected medical devices that enhance patient treatment and support healthcare professionals in decision-making. The company's technology allows for the acceleration and adjustment of bone growth, enabling healthcare providers to utilize electro-therapeutics to manage patient conditions effectively.

enGenome is a bioinformatics company focused on enhancing the diagnosis and treatment of genetic diseases through its advanced genomic interpretation and bioinformatics software. By automating variant interpretation guidelines, the company reduces the occurrence of variants of uncertain significance and provides comprehensive reports that include supporting evidence. This technology enables geneticists to accurately and swiftly identify pathogenic genomic variants, ultimately leading to improved patient outcomes. Through its omics-based reporting, enGenome aims to assist physicians in making informed decisions regarding diagnosis and therapies, thereby contributing to more effective healthcare solutions.

Epigene Labs SAS is a biotechnology firm focused on enhancing precision oncology through its advanced technology platform that utilizes artificial intelligence. Founded in 2019 and headquartered in Paris, France, with an additional office in Boston, Massachusetts, the company addresses the significant challenges of aggregating, analyzing, and visualizing extensive genomic data in cancer research. By integrating proprietary data from partners with publicly available datasets, Epigene Labs provides medical researchers with actionable insights and user-friendly analytics. The company collaborates with leading cancer centers and prominent biotech firms to develop intelligence-augmenting services that support drug discovery and research in precision oncology. Its innovative approach aims to transform genomic data into effective strategies for targeted cancer therapies.

Sequentia Biotech, founded in 2013 by Walter Sanseverino and Riccardo Aiese Cigliano, is a bioinformatics company based at the UAB Research Park. The company specializes in transforming genomic data into actionable knowledge for various sectors including academic research, plant and animal breeding, and biomedicine. Sequentia serves a diverse client base of over 30 public and private research centers, companies, and hospitals, participating in more than 160 R&D projects. The company offers cloud software, custom software, and bioinformatics consulting services, with notable contributions such as two open-source biodata banks and an award-winning R&D line called Tricopharming, established in 2014. Sanseverino and Aiese have published over 40 scientific articles in high-impact journals, underscoring the company's expertise in omics sciences.

Amadix is a biotechnology company focused on the development and commercialization of innovative cancer diagnostic technologies that address unmet medical needs in oncology. The company aims to enhance early cancer detection through non-invasive methods, significantly improving patient outcomes and reducing the complications associated with traditional invasive procedures like tumor biopsies. Amadix's flagship product, Colofast, is a non-invasive blood test designed for the screening of colorectal cancer and advanced adenoma diagnosis, targeting the high mortality rate associated with this disease. The company is committed to validating its products through international multicenter studies to ensure clinical efficacy before global commercialization. The team at Amadix comprises experienced professionals with extensive backgrounds in oncology diagnostics, the pharmaceutical industry, and biotechnology, supported by an independent board of advisors with deep expertise in oncology and diagnostics, guiding the company's strategic and commercial efforts.

Sequentia Biotech, founded in 2013 by Walter Sanseverino and Riccardo Aiese Cigliano, is a bioinformatics company based at the UAB Research Park. The company specializes in transforming genomic data into actionable knowledge for various sectors including academic research, plant and animal breeding, and biomedicine. Sequentia serves a diverse client base of over 30 public and private research centers, companies, and hospitals, participating in more than 160 R&D projects. The company offers cloud software, custom software, and bioinformatics consulting services, with notable contributions such as two open-source biodata banks and an award-winning R&D line called Tricopharming, established in 2014. Sanseverino and Aiese have published over 40 scientific articles in high-impact journals, underscoring the company's expertise in omics sciences.

Operator of a medical technology company intended to offer affordable EEG (electroencephalogram) scans and interpretations for epilepsy patients. The company provides an affordable, Bluetooth-enabled electrode cap to access and interpret medical information from the brain which is uploaded to the cloud, and offers remote diagnosis by neurologists, enabling patients in low- and middle-income countries to get diagnosed and treated for epilepsy.

PKvitality is a bio-wearable company based in Paris, France, that specializes in innovative health monitoring solutions. Founded in 2017, the company has developed K’Track, a line of trackers that assess key physiological markers through skin analysis, eliminating the need for blood samples. Its flagship product, K’Watch Glucose, is a continuous glucose monitoring device designed in the form of a smartwatch, featuring a micro-needle sensor that allows diabetics to monitor their glucose levels painlessly and discreetly. The device provides real-time alerts through on-body vibrations for hypo or hyperglycemic episodes, enhancing user convenience and safety. In addition to glucose monitoring, PKvitality is expanding its offerings to include continuous lactate monitoring and multi-analyte monitors, further advancing the field of wearable health technology.

Idoven is a pioneering company that has created the world’s first cardiology-as-a-service platform utilizing artificial intelligence to enhance the capabilities of both cardiologists and non-cardiology clinicians in identifying, triaging, and diagnosing patients on a large scale. The company's innovative software analyzes prolonged electrocardiograms to detect early signs of heart problems, including alterations in cardiac electrical activity and arrhythmias, thereby facilitating timely diagnoses and preventing serious conditions such as myocardial infarction and sudden cardiac death. Idoven has established partnerships with prominent organizations, including AstraZeneca, Abbott, and GE Healthcare, and has gained recognition in the healthcare sector, receiving multiple awards for its AI technology from notable institutions in Europe and the United States. The company has also been recognized as one of the top 50 companies in Digital Health for 2023 by CB Insights.

Positrigo AG is a Zurich-based company specializing in the development, manufacturing, and sales of dedicated brain positron emission tomography (PET) scanners. Founded in 2018, Positrigo focuses on providing functional imaging solutions that facilitate the early detection of neurodegenerative diseases, particularly Alzheimer's disease, as well as other conditions like Lewy body dementia, vascular dementia, and frontotemporal dementia. The company's PET scanners are designed to be accessible and affordable, enabling healthcare professionals to diagnose and monitor treatment effectively, while also contributing to the advancement of new therapies in the field of neurology.

Vivasure Medical Limited is a medical device company based in Galway, Ireland, that specializes in the research, development, and manufacture of arterial and venous closure devices utilizing its patented PerQseal technology. The company focuses on creating polymer implants and delivery systems aimed at minimally invasive vessel closures, primarily in cardiology, interventional radiology, and vascular surgery. Its flagship product is an absorbable patch-based large-bore percutaneous closure device, designed to effectively close large arteriotomies resulting from transcatheter procedures, including transcatheter aortic valve replacement and endovascular aneurysm repair. Founded in 2008, Vivasure Medical is committed to advancing techniques that enhance patient outcomes in vascular access procedures.

NanoVation specializes in developing monitoring solutions for patients with chronic respiratory diseases, such as chronic obstructive pulmonary disease and asthma. The company has created a nanosensor-based wearable device that enables the early detection of subtle changes in a patient's respiratory condition. By identifying these changes before they reach critical stages, NanoVation aims to improve patient outcomes through timely interventions and reduce the risk of exacerbations and unnecessary hospitalizations. Founded by Gregory Shuster, NanoVation focuses on empowering healthcare professionals with the tools needed to monitor patients at home effectively, facilitating proactive measures in respiratory care.

GlucoModicum is a company dedicated to developing innovative, needle-free health and biomarker monitoring technologies. It specializes in creating a glucose monitoring solution that utilizes precise magnetohydrodynamic technology. The company's primary product is a wrist-worn device equipped with a replaceable sensor that allows users to continuously monitor glucose levels in their blood. This device is designed for diabetic patients, enabling them to track their health effectively and manage their blood glucose levels independently. The data collected by the device can be synchronized with smartphones and uploaded to the cloud, providing users with valuable insights into their health.

RadonTec GmbH, founded in 2017 and located in Wittislingen, Bayern, specializes in radon detection and control system solutions aimed at ensuring radon-safe construction. The company develops a comprehensive Radon Detection and Control System (RDC) that employs advanced sensor technology to actively manage ventilation systems and fans. In addition to its primary offerings, RadonTec provides a range of services, including workplace and interior radon measurement, control measurements, and assessments of building materials. This enables customers to obtain reliable radiation measurement devices and accessories tailored for both home and professional applications, promoting safety in environments affected by radon exposure.

Glycanostics is a start-up focused on developing innovative cancer diagnostic tests, specifically targeting prostate cancer. The company specializes in creating clinically validated and registered non-invasive liquid biopsy tests that analyze glycan changes on proteins, such as prostate-specific antigen (PSA). This technology aims to deliver accurate and affordable diagnostic solutions, assisting healthcare professionals in making informed decisions regarding the necessity of biopsies and monitoring patients post-biopsy. Through its advancements in cancer diagnostics, Glycanostics seeks to improve early detection and patient outcomes.

Intelligent Implants is a bioelectronics company based in Cork, Ireland, founded in 2014 by Erik Zellmer, Rory Murphy, Martin Larsson, and John Zellmer. The company specializes in wireless implantable electronics designed to stimulate, steer, and monitor bone growth. Its innovative electrotherapeutic devices provide solutions to treat diseases and facilitate the recovery of bone and other tissues. By integrating data, engineering, and medical expertise, Intelligent Implants develops active and connected medical devices that enhance patient treatment and support healthcare professionals in decision-making. The company's technology allows for the acceleration and adjustment of bone growth, enabling healthcare providers to utilize electro-therapeutics to manage patient conditions effectively.

GlucoModicum is a company dedicated to developing innovative, needle-free health and biomarker monitoring technologies. It specializes in creating a glucose monitoring solution that utilizes precise magnetohydrodynamic technology. The company's primary product is a wrist-worn device equipped with a replaceable sensor that allows users to continuously monitor glucose levels in their blood. This device is designed for diabetic patients, enabling them to track their health effectively and manage their blood glucose levels independently. The data collected by the device can be synchronized with smartphones and uploaded to the cloud, providing users with valuable insights into their health.

ADVITOS GmbH is a Munich-based company that specializes in the design, development, and marketing of extracorporeal multiple organ support therapy products for hospitals in Germany. Founded in 2004, the company offers an innovative treatment method known as ADVanced organ support, which utilizes albumin dialysis to facilitate the removal of various toxins from the liver, lungs, and kidneys. This method enables the elimination of CO2, hepatic toxins, and both water-soluble and protein-bound nephrotoxins, while also addressing metabolic and respiratory acidosis. The ADVOS system operates using standard dialysis accesses and flow rates, distinguishing itself by not requiring gas exchangers for CO2 removal.

Idoven is a pioneering company that has created the world’s first cardiology-as-a-service platform utilizing artificial intelligence to enhance the capabilities of both cardiologists and non-cardiology clinicians in identifying, triaging, and diagnosing patients on a large scale. The company's innovative software analyzes prolonged electrocardiograms to detect early signs of heart problems, including alterations in cardiac electrical activity and arrhythmias, thereby facilitating timely diagnoses and preventing serious conditions such as myocardial infarction and sudden cardiac death. Idoven has established partnerships with prominent organizations, including AstraZeneca, Abbott, and GE Healthcare, and has gained recognition in the healthcare sector, receiving multiple awards for its AI technology from notable institutions in Europe and the United States. The company has also been recognized as one of the top 50 companies in Digital Health for 2023 by CB Insights.

Smart4Diagnostics GmbH, founded in 2018 and based in Munich, Germany, specializes in the manufacturing of digital data fingerprints for human blood samples. The company has developed a device designed for precise measurement and analysis of blood samples, contributing to advancements in medical diagnostics. By focusing on innovative solutions in the healthcare sector, Smart4Diagnostics aims to enhance the accuracy and efficiency of blood analysis, thereby improving patient outcomes.

MedTrace Pharma A/S, founded in 2015 and based in Kongens Lyngby, Denmark, specializes in the development of innovative solutions for positron emission tomography (PET) imaging. The company has created an automated system, known as MT-100, which efficiently produces and injects 15O-water, a radioactive tracer essential for enhanced imaging. This system is designed to integrate seamlessly with in-house cyclotrons and PET scanners, significantly increasing the sensitivity of patient analysis while improving throughput by up to four times compared to conventional methods. Additionally, MedTrace Pharma develops the aQuant analytical platform, which aids in interpreting PET scan results, further optimizing the diagnostic process. With additional offices in Boston, Massachusetts, and Uppsala, Sweden, MedTrace is focused on advancing the capabilities of clinical imaging through automation and innovative technology.

Novus Diagnostics is focused on developing an innovative diagnostic device aimed at detecting sepsis. This technology allows for the rapid and automated identification of pathogens present in whole blood samples. By providing results in minutes, Novus Diagnostics empowers healthcare providers to initiate effective treatment for sepsis patients quickly and efficiently. The approach not only enhances patient care but also aims to reduce costs associated with sepsis management.

CorWave is a company focused on developing innovative implanted cardiac support devices aimed at improving the quality of life for patients suffering from heart failure. Its flagship product, the CorWave LVAD, employs a unique undulating disc wave pumping mechanism, which replaces traditional high-speed impellers used in current continuous flow rotary pumps. This design significantly reduces trauma to blood, thereby minimizing complications such as clotting and bleeding. The CorWave pump generates a pulsatile flow that closely resembles the natural heartbeat, addressing a key limitation of existing LVADs that provide only continuous flow. Additionally, the device's low power consumption and compact size facilitate its potential for complete implantation, enhanced by a wireless energy transfer system. Through these advancements, CorWave aims to alleviate the burdens associated with heart failure and invasive surgical procedures.

Kinepict Ltd. is a developer of advanced medical imaging technology aimed at enhancing the safety and efficacy of X-ray angiography. The company utilizes patented kinetic imaging techniques to capture and present motion-related functional information from X-ray image series. This innovative approach results in a new type of imaging known as contrast enhanced image (CEI) and digital variance angiography (DVA), which allows healthcare professionals to visualize the movement of contrast agents within the body. By providing detailed insights into organ function while significantly reducing the required doses of contrast medium and X-ray radiation, Kinepict's technology enhances diagnostic capabilities and promotes patient safety.

Kinepict Ltd. is a developer of advanced medical imaging technology aimed at enhancing the safety and efficacy of X-ray angiography. The company utilizes patented kinetic imaging techniques to capture and present motion-related functional information from X-ray image series. This innovative approach results in a new type of imaging known as contrast enhanced image (CEI) and digital variance angiography (DVA), which allows healthcare professionals to visualize the movement of contrast agents within the body. By providing detailed insights into organ function while significantly reducing the required doses of contrast medium and X-ray radiation, Kinepict's technology enhances diagnostic capabilities and promotes patient safety.

EyeControl is a medical technology company that develops innovative communication solutions for individuals with severe speech impairments, such as those affected by locked-in syndrome or ALS. Their flagship product is an intuitive glass frame equipped with an infrared camera, which translates eye movements into spoken commands via a connected computer and earphones/speaker. This device aims to enhance patients' quality of life by facilitating easier communication and improving access to healthcare services.

EyeControl is a medical technology company that develops innovative communication solutions for individuals with severe speech impairments, such as those affected by locked-in syndrome or ALS. Their flagship product is an intuitive glass frame equipped with an infrared camera, which translates eye movements into spoken commands via a connected computer and earphones/speaker. This device aims to enhance patients' quality of life by facilitating easier communication and improving access to healthcare services.

Positrigo AG is a Zurich-based company specializing in the development, manufacturing, and sales of dedicated brain positron emission tomography (PET) scanners. Founded in 2018, Positrigo focuses on providing functional imaging solutions that facilitate the early detection of neurodegenerative diseases, particularly Alzheimer's disease, as well as other conditions like Lewy body dementia, vascular dementia, and frontotemporal dementia. The company's PET scanners are designed to be accessible and affordable, enabling healthcare professionals to diagnose and monitor treatment effectively, while also contributing to the advancement of new therapies in the field of neurology.

Positrigo AG is a Zurich-based company specializing in the development, manufacturing, and sales of dedicated brain positron emission tomography (PET) scanners. Founded in 2018, Positrigo focuses on providing functional imaging solutions that facilitate the early detection of neurodegenerative diseases, particularly Alzheimer's disease, as well as other conditions like Lewy body dementia, vascular dementia, and frontotemporal dementia. The company's PET scanners are designed to be accessible and affordable, enabling healthcare professionals to diagnose and monitor treatment effectively, while also contributing to the advancement of new therapies in the field of neurology.

Onera Health, Inc. specializes in sleep diagnostic solutions and services aimed at identifying sleep disorders such as insomnia, sleep apnea, and narcolepsy. Founded in 2017 and headquartered in Palo Alto, California, with a research and development office in Eindhoven, the Netherlands, the company utilizes advanced sleep diagnostic patch systems that collect and analyze sleep data. These innovative solutions are designed to enhance patient care by providing comprehensive sleep test data to healthcare professionals across various settings, thereby improving the management of sleep-related ailments and potentially benefiting other medical fields through remote monitoring of chronic conditions. Onera Health's mission is to improve the health and quality of life for individuals struggling with sleep issues while also contributing to cost reductions in healthcare.

SiriusXT Limited is a company that specializes in the development and manufacturing of soft x-ray microscopes, specifically the SXT system. Founded in 2015 and headquartered in Dublin, Ireland, SiriusXT's innovative technology utilizes a vacuum-based laser-produced plasma light source to enable high-resolution imaging of biological samples. The SXT system is designed for researchers in disease research and drug discovery, providing a crucial tool for visualizing the 3D internal structures of cells in their native, fully hydrated state without the need for stains or contrast agents. This capability is essential for understanding disease pathways, protein-drug interactions, and bio-engineering processes. SiriusXT is recognized for offering the world's first high-throughput, benchtop soft x-ray tomography system, allowing users to produce detailed tomographs quickly and efficiently.

Ilya Pharma AB, established in 2016 and headquartered in Uppsala, Sweden, specializes in developing biological drugs for treating skin and mucosal wounds. The company's innovative approach involves genetically modifying lactic acid bacteria, commonly found in yogurt, to produce substances that accelerate wound healing. Ilya Pharma focuses on both acute and chronic wounds, with a particular emphasis on addressing the unique challenges faced by diabetic patients.

Ilya Pharma AB, established in 2016 and headquartered in Uppsala, Sweden, specializes in developing biological drugs for treating skin and mucosal wounds. The company's innovative approach involves genetically modifying lactic acid bacteria, commonly found in yogurt, to produce substances that accelerate wound healing. Ilya Pharma focuses on both acute and chronic wounds, with a particular emphasis on addressing the unique challenges faced by diabetic patients.

Neuro Event Labs Oy, established in 2015 and headquartered in Tampere, Finland, specializes in developing artificial intelligence-based software for epilepsy patient monitoring. Their primary product collects accurate seizure data from patients at home and in hospitals, which is then analyzed and relayed to physicians for informed treatment decisions. This solution was developed in close collaboration with leading Finnish hospitals.

Sensocure is a medical technology company specializing in the development and delivery of sensors for healthcare applications. Its flagship product, IscAlert™, is a patented, body-implantable micro biosensor designed to monitor blood flow in human organs. This innovative technology enables real-time monitoring of body functions and early detection of organ damage, with applications in various surgical procedures such as cardiac, vascular, transplant, and reconstructive surgeries. Sensocure aims to address the significant need for early diagnostics in conditions related to insufficient blood supply to vital organs, which is a leading cause of death in the Western world. The company's first sensor version is CE marked and FDA approved.

ADmit Therapeutics, S.L. is a biotechnology company based in Begues, Spain, focused on developing diagnostic tests for the early detection of Alzheimer’s disease. Founded in 2017, the company utilizes epigenetic analysis of blood samples to identify a series of mitochondrial biomarkers, which are unrelated to traditional markers such as ß-amyloid or tau. By employing next-generation sequencing to analyze methylcytosines in mitochondrial DNA, ADmit Therapeutics provides medical practitioners with a simplified method for detecting early-stage Alzheimer’s disease. This innovative approach not only aids in diagnosis but also supports pharmaceutical companies in the accelerated identification of potential curative drugs.